Back to Journals » OncoTargets and Therapy » Volume 14

PDIA4 Correlates with Poor Prognosis and is a Potential Biomarker in Glioma

Authors Li H, Liu Q, Xiao K, He Z, Wu C, Sun J, Chen X, Chen S, Yang J, Ma Q, Su J

Received 22 October 2020

Accepted for publication 21 December 2020

Published 8 January 2021 Volume 2021:14 Pages 125—138

DOI https://doi.org/10.2147/OTT.S287931

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Takuya Aoki


Haoyu Li,1 Qing Liu,1 Kai Xiao,1 Zhengxi He,2 Chao Wu,3 Jianjun Sun,3 Xin Chen,3 Suhua Chen,3 Jun Yang,3 Qianquan Ma,3 Jun Su4

1Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, People’s Republic of China; 2Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, People’s Republic of China; 3Department of Neurosurgery, Peking University Third Hospital, Peking University, Beijing 100191, People’s Republic of China; 4Department of Neurosurgery, Hunan Children’s Hospital, Changsha 410007, Hunan, People’s Republic of China

Correspondence: Qianquan Ma; Jun Su Email mqq0716@live.com; neurodoc_su@126.com

Purpose: Gliomas, characterized by aggressiveness and invasiveness, remain incurable after conventional therapies. The molecular mechanisms driving the progression and maintenance of glioma are still poorly understood.
Methods: The TCGA and CGGA databases were chosen for bioinformatics analysis. Gene expression profiling interactive analysis (GEPIA) was performed for differential analysis. The Kaplan–Meier method was chosen for survival analysis. Analysis of stromal and immune infiltration was performed using the ESTIMATE algorithm and xCell package. qPCR and Western blotting were performed to measure the expression of PDIA4 at the mRNA and protein levels. IHC was performed to detect the expression of PDIA4 in glioma tissues. The viability of glioma cells was evaluated by the CCK8 assay.
Results: In this study, we identified high PDIA4 expression in gliomas that correlated with poor prognosis. The association between IDH1 and different glioma patterns also indicated the potential biological role of PDIA4 in tumor development. Mechanistically, PDIA4 interacted with multiple immunological components to promote an immunosuppressive tumor microenvironment (TME). Knockdown of PDIA4 significantly impaired the proliferation of GBM cells.
Conclusion: Our results confirm that PDIA4 is an efficient biomarker of gliomas, with clinical implications for prognosis and therapeutic strategies.

Keywords: PDIA4, glioma, prognosis, biomarker, immune cells

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]